Granisetron 1 Mg/Ml (1 Ml) Fresenius, Granisetron 1 Mg/Ml (3 Ml) Fresenius 1 ml, 3 ml Concentrate for solution for injection/infusion.
PDF Leaflet Revision Date: 29 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative.
Dosage (summary)
Adults: 1-3 mg IV/IM prior to chemotherapy; max 9 mg/24h.
Onset of Action / Duration
Onset: 30 secs, Duration: up to 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Preferable to avoid during pregnancy; breastfeeding not advisable.
Key Drug Interactions
- QT prolonging agents
- Ketoconazole
- SSRIs
- SNRIs
Contraindications
- Hypersensitivity to granisetron
- Children under 2 years
- Congenital long QT syndrome
Common side effects
- Headache
- Constipation
- Dizziness
- Somnolence
Counselling Points
- Administer prior to chemotherapy
- Monitor for signs of myocardial ischaemia
- Avoid in pregnancy and breastfeeding
Serious warnings
- May cause dysrhythmias
- Monitor for serotonin syndrome
- Risk of myocardial ischaemia
On This Page
Connecting to Document Server
Decrypting and optimizing pharmaceutical leaflet...
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
